Patents Assigned to Annji Pharmaceutical Co., Ltd.
-
Patent number: 11535598Abstract: Histone deacetylases (HDACs) inhibitors are disclosed according to the following structural formula. The moiety A is a benzene ring, optionally substituted. The moiety B is a benzene ring attached at the 1,4 or 1,3 position, or a cyclohexane ring attached at the 1,4 position, optionally substituted. R and Z are further substituents. The HDACs inhibitors possess cytotoxicities to various cancer cell lines. They are useful for treating a tumor associated with deregulation of the activity of histone deacetylases in a subject in need thereof, in one embodiment, the HDACs inhibitors of the invention are useful for treating glioma, breast cancer, colon cancer, target cell lung cancer, adenocarcinoma of the lung, small cell lung cancer, stomach cancer, liver cancer, ovary adenocarcinoma, pancreas carcinoma, prostate carcinoma, promyiocytic leukemia, chronic myelocytic leukemia, or acute lymphocytic leukemia in a subject in need thereof.Type: GrantFiled: May 15, 2018Date of Patent: December 27, 2022Assignee: AnnJi Pharmaceutical Co., Ltd.Inventors: Ji-Wang Chern, Chao-Wu Yu, Jia-Rong Liu, Yi-Hsun Ho, Chia-Yu Wu, Chan-Hui Huang, Pei-Yun Hung
-
Patent number: 11413256Abstract: The invention provides a method for treating a neurodegenerative disorder in a subject in need of such treatment, comprising administrating to said subject a compound with (substituted phenyl)-propenal moiety.Type: GrantFiled: December 31, 2019Date of Patent: August 16, 2022Assignee: Annji Pharmaceutical Co., Ltd.Inventor: Hardy W. Chan
-
Patent number: 9387209Abstract: Histone deacetylases inhibitors (HDACIs) and compositions comprising the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit are also disclosed. In one aspect, the invention relates to a compound having the structure or a pharmaceutically acceptable salt, a solvate or hydrate, a prodrug, or a metabolite thereof. In one embodiment of the invention, R1 is ethyl; R2 is 2-phenylethyl; R3 is hydrogen; R4 is fluoro; R5 is (2E)-3-N-hydroxyamino-3-oxo-propenyl; and R6 is hydrogen, or a salt thereof. In another embodiment of the invention, R1 is ethyl; R2 is 2-phenylethyl; R3 is hydrogen; R4 is (2E)-3-N-hydroxyamino-3-oxo-propenyl; R5 is chloro or fluoro; and R6 is hydrogen, or a salt thereof.Type: GrantFiled: April 2, 2013Date of Patent: July 12, 2016Assignee: ANNJI PHARMACEUTICAL CO., LTD.Inventors: Ji-Wang Chern, Chao-Wu Yu, Pei-Teh Chang
-
Patent number: 9302992Abstract: Novel quinoline derivatives are disclosed. Also disclosed are synthesis and use thereof for treating neurodegenerative diseases.Type: GrantFiled: April 2, 2013Date of Patent: April 5, 2016Assignee: ANNJI PHARMACEUTICAL CO., LTD.Inventors: Ji-Wang Chern, Chen-Wei Huang, Pei-Teh Chang, Rahul Subhash Talekar
-
Patent number: 9155739Abstract: Histone deacetylases inhibitors (HDACIs) and methods for treating cancer in a subject in need thereof are disclosed. The HDACIs comprise a compound of Formula X. or a pharmaceutically acceptable salt thereof. In one embodiment of the invention, R1 is ethyl; R2 is 2-phenylethyl; R3 is hydrogen; R4 is fluoro; R5 is (2E)-3-N-hydroxyamino-3-oxo-propenyl; and R6 is hydrogen, or a salt thereof. In another embodiment of the invention, R1 is ethyl; R2 is 2-phenylethyl; R3 is hydrogen; R4 is (2E)-3-N-hydroxyamino-3-oxo-propenyl; R5 is chloro or fluoro; and R6 is hydrogen.Type: GrantFiled: March 23, 2015Date of Patent: October 13, 2015Assignee: ANNJI PHARMACEUTICAL CO., LTD.Inventors: Ji-Wang Chern, Chao-Wu Yu, Pei-Teh Chang
-
Patent number: 8969361Abstract: Cyclopropanecarboxylate esters of purine analogues, method of making and using the same for treating herpes virus infections and tumors are disclosed.Type: GrantFiled: April 2, 2013Date of Patent: March 3, 2015Assignee: Annji Pharmaceutical Co., Ltd.Inventors: Ji-Wang Chern, Shin-Yu Lai, Pei-Teh Chang
-
Patent number: 8946282Abstract: A novel class of indoline-2-one derivatives are disclosed. These compounds are protein kinase inhibitors which are useful for treating hyperproliferative diseases such as cancer.Type: GrantFiled: April 3, 2013Date of Patent: February 3, 2015Assignee: Annji Pharmaceutical Co., Ltd.Inventors: Ji-Wang Chern, Ajit Dhananjay Jagtap, Hsiao-Chun Wang, Grace Shiahuy Chen
-
Publication number: 20140296251Abstract: Novel quinoline derivatives are disclosed. Also disclosed are synthesis and use thereof for treating neurodegenerative diseases.Type: ApplicationFiled: April 2, 2013Publication date: October 2, 2014Applicant: Annji Pharmaceutical Co., Ltd.Inventors: Ji-Wang Chern, Chen-Wei Huang, Pei-Teh Chang, Rahul Subhash Talekar
-
Publication number: 20130281451Abstract: A novel class of indoline-2-one derivatives are disclosed. These compounds are protein kinase inhibitors which are useful for treating hyperproliferative diseases such as cancer.Type: ApplicationFiled: April 3, 2013Publication date: October 24, 2013Applicant: ANNJI PHARMACEUTICAL CO., LTD.Inventors: Ji-Wang Chern, Ajit Dhananjay Jagtap, Hsiao-Chun Wang, Grace Shiahuy Chen
-
Publication number: 20130267542Abstract: Histone deacetylases inhibitors (HDACIs) and compositions comprising the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit are also disclosed.Type: ApplicationFiled: April 2, 2013Publication date: October 10, 2013Applicant: Annji Pharmaceutical Co., Ltd.Inventors: Ji-Wang CHERN, Chao-Wu YU, Pei-Teh CHANG